Companies: 10,795·Total market cap: $144.5T
Immunovant, Inc.

Immunovant, Inc.

IMVTNASDAQHealthcare● Active
$30.87
$-0.24(-0.77%)
Market Cap$6.3B
P/E Ratio—
52W High$36.285
52W Low$14.32
Cash on HandFinancialsRevenue

Immunovant, Inc. (IMVT) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

IMVT · cash on hand · updated Mar 31, 2026

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$902.1M▲ +26.4% vs prior year
FY · as of Mar 31, 2026 · Reported in USD
Cash & Cash Equiv. (CCE)
$902.1M
cashAndCashEquivalents
Short-Term Investments
$0
shortTermInvestments
YoY Change vs Prior Year
+26.4%
vs prior fiscal year
Latest Quarter
$902.1M
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: March 31, 2026

Net cash vs debt

Cash & ST Investments$902.1MCash on Hand
Total Debt$72,000Total Debt
Net Cash / Net Debt+$902.0MNet Cash Position
Cash vs Debt Ratio
Cash 100%Debt 0%

Immunovant, Inc. has a net cash position of $902.0M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$902.1M − $72,000 = +$902.0M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
IMVT annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Mar 31, 2026Latest$902.1M+26.4%
Mar 31, 2025$714.0M+12.4%
Mar 31, 2024$635.4M+68.7%
Mar 31, 2023$376.5M-23.8%
Mar 31, 2022$493.8M+23.4%
IMVT cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.7%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Immunovant, Inc.
Immunovant, Inc.YOU
IMVT
$902.1M14.2%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Immunovant, Inc. (IMVT) cash on hand as of March 31, 2026 is $902.1M, comprising $902.1M in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Immunovant, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Immunovant, Inc. cash reserves or cash position.

Immunovant, Inc. annual cash on hand history shows increased +26.4% in 2026: increased +26.4% in 2026. Immunovant, Inc. cash reserves in 2026 reflect the company's capital allocation strategy.

Immunovant, Inc. carries total debt of $72,000 against cash of $902.1M, resulting in a net cash position of +$902.0M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

IMVT cash on hand · 5 questions

As of March 31, 2026, Immunovant, Inc. (IMVT) has $902,110,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $902,110,000 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $902,110,000. Data sourced from the annual 10-K filing via FMP.

IMVT cash on handIMVT cash reservesIMVT cash 2026how much cash does IMVT have

▸ Source: FMP /balance-sheet-statement · US GAAP · Immunovant, Inc. · Immunovant, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: March 31, 2026